These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34423904)

  • 21. A randomized controlled trial of intranasal ketamine in major depressive disorder.
    Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder.
    Dijkstra FM; van de Loo AJ; Abdulahad S; Bosma ER; Hartog M; Huls H; Kuijper DC; de Vries E; Solanki B; Singh J; Aluisio L; Zannikos P; Stuurman FE; Jacobs GE; Verster JC
    J Psychopharmacol; 2022 May; 36(5):614-625. PubMed ID: 35212235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
    Dean RL; Marquardt T; Hurducas C; Spyridi S; Barnes A; Smith R; Cowen PJ; McShane R; Hawton K; Malhi GS; Geddes J; Cipriani A
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD011611. PubMed ID: 34623633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketamine and other glutamate receptor modulators for depression in adults.
    Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice.
    Rajagopal L; Huang M; He W; Ryan C; Elzokaky A; Banerjee P; Meltzer HY
    Behav Brain Res; 2022 Aug; 432():113964. PubMed ID: 35718230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
    Price RB; Iosifescu DV; Murrough JW; Chang LC; Al Jurdi RK; Iqbal SZ; Soleimani L; Charney DS; Foulkes AL; Mathew SJ
    Depress Anxiety; 2014 Apr; 31(4):335-43. PubMed ID: 24668760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating drugged driving: Effects of exemplar pain and anxiety medications.
    Brown TL; Milavetz G; Gaffney G; Spurgin A
    Traffic Inj Prev; 2018 Feb; 19(sup1):S97-S103. PubMed ID: 29584496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.
    Kroboth PD; Folan MM; Lush RM; Chaikin PC; Shukla UA; Barbhaiya R; Salazar DE
    J Clin Psychopharmacol; 1995 Oct; 15(5):306-19. PubMed ID: 8830061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice.
    Pham TH; Mendez-David I; Defaix C; Guiard BP; Tritschler L; David DJ; Gardier AM
    Neuropharmacology; 2017 Jan; 112(Pt A):198-209. PubMed ID: 27211253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.
    Leufkens TR; Vermeeren A; Smink BE; van Ruitenbeek P; Ramaekers JG
    Psychopharmacology (Berl); 2007 May; 191(4):951-9. PubMed ID: 17219217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.
    Taylor JH; Landeros-Weisenberger A; Coughlin C; Mulqueen J; Johnson JA; Gabriel D; Reed MO; Jakubovski E; Bloch MH
    Neuropsychopharmacology; 2018 Jan; 43(2):325-333. PubMed ID: 28849779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants.
    Reed JL; Nugent AC; Furey ML; Szczepanik JE; Evans JW; Zarate CA
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2019 Jul; 4(7):610-618. PubMed ID: 30826253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Driving impairment and altered ocular activity under the effects of alprazolam and alcohol: A randomized, double-blind, placebo-controlled study.
    Aitken B; Hayley AC; Ford TC; Geier L; Shiferaw BA; Downey LA
    Drug Alcohol Depend; 2023 Oct; 251():110919. PubMed ID: 37611483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities.
    Li M; Demenescu LR; Colic L; Metzger CD; Heinze HJ; Steiner J; Speck O; Fejtova A; Salvadore G; Walter M
    Neuropsychopharmacology; 2017 May; 42(6):1201-1209. PubMed ID: 27604568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
    Williams NR; Heifets BD; Blasey C; Sudheimer K; Pannu J; Pankow H; Hawkins J; Birnbaum J; Lyons DM; Rodriguez CI; Schatzberg AF
    Am J Psychiatry; 2018 Dec; 175(12):1205-1215. PubMed ID: 30153752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
    Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
    J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers.
    Barbanoj MJ; Clos S; Romero S; Morte A; Giménez S; Lorenzo JL; Luque A; Dal-Ré R
    Neuropsychobiology; 2005; 51(3):134-47. PubMed ID: 15838185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.